'On standalone basis

Quarter ended December 2025 compared with Quarter ended December 2024.

Net sales (including other operating income) of RPG Life Sciences has increased 4.24% to Rs 180.03 crore.  Operating profit margin has declined from 28.46% to 22.09%, leading to 19.12% decline in operating profit to Rs 39.76 crore.  Raw material cost as a % of total sales (net of stock adjustments) increased from 17.81% to 17.97%.   Purchase of finished goods cost rose from 13.39% to 22.54%.   Employee cost increased from 16.94% to 18.25%.   Other expenses fell from 22.85% to 20.69%.   

Other income up 3.02% to Rs 3.41 crore.  PBIDT fell 17.72% to Rs 43.17 crore.  Provision for interest up 108.33% to Rs 0.25 crore.  

PBDT fell 18.01% to Rs 42.92 crore.  Provision for depreciation down 1.47% to Rs 5.38 crore.  

Profit before tax down 19.94% to ...

• 

  (05-Feb-2025)

  Castrol India

  Expects EBITDA margin of 22%-25% for CY25
• 

  (10-Feb-2023)

  Deepak Nitrite

  Plans capex of about Rs 1500 crore for FY23 and FY24
• 

  (09-Feb-2023)

  Mayur Uniquoters

  Targets revenue of Rs 1000 crore in FY24
• 

  (31-Jan-2023)

  Tega industries

  Capex plan is US$ 30-32 million for next three years